AIM ImmunoTech Inc. AIM
Set alert
At close · Oct 30
After hours · Oct 30, 7:50 PM ET
- YTD
- -85.95%
- 1 year
- -92.81%
- Open
- 0.164
- Prev close
- 0.161
- Mkt cap
- 6.16M
- Vol
- 386.13K
- Avg vol
- 4.70M
- EPS
- -2.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1545
- High
- 0.1638
- Forward P/E
- -0.48
- Beta
- -0.36
- Short ratio
- 1.63
- Inst. own
- 14.07%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.232
- 200-d avg
- 0.338
- 1y target
- 2.75
3M chart
Signals (17)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 15, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 14, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 24, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 22, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 11, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Aug 31, 2026 | 2 months ago |
| SMA: Bullish | Aug 28, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 12.44M
- Enterprise value
- 6.04M
- Trailing P/E
- 0.00
- Forward P/E
- -0.48
- PEG ratio
- 0.00
- Price / sales
- 61.88
- Price / book
- 1.01
- EPS (TTM)
- -0.47
- Beta
- -0.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 201.00K
- Revenue growth
- 19.00%
- Free cash flow
- -16.04M
- Total cash
- 10.06M
- Total debt
- 3.36M
- Return on equity
- -154.79%
- Shares outstanding
- 63.78M
- Short % of float
- 0.85%
- 50-day average
- 0.232
- 200-day average
- 0.338
Analyst view
Consensus: strong buy
- Target (low)
- 1.00
- Target (mean)
- 2.75
- Target (high)
- 4.50
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.09.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.10 | -0.06 | +0.04 | +40.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| May 16, 2024 | Mar 1, 2024 | 0.00 | -0.12 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.26 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.16 | — | — |
| Aug 15, 2023 | Jun 1, 2023 | 0.00 | -0.10 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Oct 22, 2024 | Maxim Group | main | Buy | Buy |
| Sep 3, 2024 | Ascendiant Capital | main | Buy | Buy |
| Oct 10, 2019 | Maxim Group | up | Hold | Buy |
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aimimmuno.com
News
- AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
- AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential
- AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
- Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace
- AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
- Ondine Biomedical pauses trading to raise fresh investment after positive phase III result
- 1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition
- 1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years
- Digitalbox eyes creator-led growth as it rides out Meta disruption
- AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib
Your note
Sign in to keep a note on AIM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPELROUTH STEWART L. | Director | Stock Award(Grant) | Dec 12, 2024 | 379,961 |
| BRYAN NANCY K | Director | Stock Award(Grant) | Dec 12, 2024 | 85,559 |
| EQUELS THOMAS K | Chief Executive Officer | Purchase | Dec 17, 2024 | 1,680,700 |
| MITCHELL WILLIAM M | Director | Sale | Dec 18, 2024 | 118,929 |
| RODINO PETER W III | Chief Operating Officer | Stock Award(Grant) | Aug 11, 2024 | 401,262 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 6.79% | 4,330,000 | 844.35K | Sep 29, 2024 |
| Vanguard Group Inc | 3.12% | 1,988,704 | 387.80K | Sep 29, 2024 |
| Blackrock Inc. | 1.09% | 698,267 | 136.16K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.73% | 464,016 | 90.48K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.72% | 457,767 | 89.26K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.38% | 243,208 | 47.42K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.06% | 1,311,599 | 255.76K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.97% | 620,229 | 120.94K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 303,016 | 59.09K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 71,505 | 13.94K | Oct 30, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.07% | 43,668 | 8.52K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 36,509 | 7.12K | Oct 30, 2024 |